コンテンツへスキップ
Merck
  • [Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].

[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].

No to hattatsu = Brain and development (2013-04-19)
Tae Ikeda, Kuriko Kagitani-Shimono, Yoshiko Iwatani, Yukihiro Kitai, Masaya Tachibana, Koji Tominaga, Takeshi Okinaga, Toshisaburo Nagai, Keiichi Ozono
要旨

We report a case of a 15-year-old girl with relapsing-remitting multiple sclerosis (MS) who received cyclophosphamide pulse therapy. At the age of 5 years, she displayed symptoms such as headache and unconsciousness after varicella infection as the first episode of MS. She had been treated with methylprednisolone pulse therapy, intravenous immunoglobulin, interferon-beta1b, and azathioprine. However, she had relapsed 12 times by the age of 15 years. At this time, she showed weakness and severe paralysis of her left leg, and even 1 month after methylprednisolone pulse therapy, she still had gait impairment and showed gadolinium-enhanced lesion on brain magnetic resonance imaging. We then started cyclophosphamide pulse therapy (600 mg/m2) once a month for 12 months combined with interferon-beta1a. She had no serious side effects and she could walk again after 4 months on cyclophosphamide treatment. She has been free from relapse for 2 years and 8 months until the present time. Although only a few studies have indicated the efficacy of cyclophosphamide pulse therapy for childhood MS, we consider careful use of cyclophosphamide could be one of the options for refractory childhood MS.